US2015064238A1PendingUtilityA1

Method and composition for enhancing the delivery of anti-platelet drugs for the treatment of acute stroke

53
Assignee: LIN JEN CHENGPriority: Jul 29, 2013Filed: Jul 28, 2014Published: Mar 5, 2015
Est. expiryJul 29, 2033(~7 yrs left)· nominal 20-yr term from priority
Inventors:Jen C. LinChun-Chieh LinHsu-Tung LeeYu-Ming FanJui-Chi Tsai
A61K 38/49A61K 9/5153A61K 9/127A61K 47/34A61K 31/519A61K 45/06A61P 9/10A61K 9/5031A61P 7/02
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising an anti-platelet drug and a vehicle that can reduce the binding rate of plasma proteins, so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose. By use of the neuro-protective efficacy of anti-platelet drug, the invention allows the drug to release slowly to the site of treatment by combining anti-platelet drugs with a vehicle that can reduce the binding rate of plasma proteins to effectively reduce the dose of the anti-platelet drug and consequently reduce the side effects such as hypotension caused by, administration of a high dose of the anti-platelet drugs. The invention also provides a pharmaceutical composition for enhancing treatment of acute stroke and a method for treating acute stroke using the pharmaceutical composition of the invention.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for enhancing the delivery of an anti-platelet drug for the treatment of acute stroke, comprising delivering a composition comprising
 (a) an anti-platelet drug; and   (b) a vehicle or chemical modification thereof that can reduce the binding rate of plasma proteins,   so that the anti-platelet drug can achieve the effect of treating acute stroke at a low dose,   wherein the effective amount of the anti-platelet drug is about 30 to 100 mg, and the anti-platelet drug is a phosphodiesterase inhibitor.   
     
     
         2 . The method of  claim 1 , wherein the vehicle that can reduce the binding rate of plasma proteins is a polymeric vehicle or a liposome. 
     
     
         3 . The method of  claim 2 , wherein the anti-platelet drug forms a nanoparticle with the vehicle that can reduce the binding rate of plasma proteins. 
     
     
         4 . The method of  claim 2 , wherein the polymeric vehicle is a (poly(lacitide-co-glycolide))-(ethylene glycol)-(poly(lacitide-co-glycolide) (PLGA-PEG-PLGA) polymeric vehicle. 
     
     
         5 . The method of  claim 2 , wherein the weight ratio of the anti-platelet drug to the polymeric vehicle is 1:5 to 1:15 
     
     
         6 . The method of  claim 1 , wherein the phosphodiesterase inhibitor is Dipyridamole. 
     
     
         7 . The method of  claim 1 , wherein the composition further comprises a thrombolytic agent. 
     
     
         8 . The method of  claim 7 , wherein the thrombolytic agent is a recombinant-type plasminogen activator (rt-PA). 
     
     
         9 . A pharmaceutical composition comprising:
 (a) an anti-platelet drug; and   (b) a vehicle that can reduce the binding rate of plasma proteins,   wherein the effective amount of the anti-platelet drug is about 30 to 100 mg, and the anti-platelet drug is a phosphodiesterase inhibitor.   
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the vehicle that can reduce the binding rate of plasma proteins is a polymeric vehicle or a liposome. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the anti-platelet drug forms a nanoparticle with the vehicle that can reduce the binding rate of plasma proteins. 
     
     
         12 . The pharmaceutical composition of  claim 10 , wherein the polymeric vehicle is a (poly(lacitide-co-glycolide))-(ethylene glycol)-(poly(lacitide-co-glycolide) (PLGA-PEG-PLGA) polymeric vehicle. 
     
     
         13 . The pharmaceutical composition of  claim 10 , wherein the weight ratio of the anti-platelet drug to the polymeric vehicle is 1:5 to 1:15. 
     
     
         14 . The pharmaceutical composition of  claim 9 , wherein the anti-platelet drug is Dipyridamole. 
     
     
         15 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutical composition further comprises a thrombolytic agent. 
     
     
         16 . The pharmaceutical composition of  claim 9 , wherein the thrombolytic agent is a recombinant-type plasminogen activator (rt-PA). 
     
     
         17 . A method for the treatment of acute stroke comprising administering the pharmaceutical composition of  claim 9  to a subject suffering acute stroke. 
     
     
         18 . The method of  claim 17 , wherein the antiplatelet drug is Dipyridamole. 
     
     
         19 . The method of  claim 17 , wherein the pharmaceutical composition further comprises a thrombolytic agent. 
     
     
         20 . The method of  claim 18 , wherein the thrombolytic agent is a recombinant-type plasminogen activator (rt-PA).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.